Combination Chemotherapy With Sildenafil Plus Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer

• Status: Completed
• Trial end date: 2010-12-01
• Target enrollment: 0
• Participant gender: All

Summary

A comparison of combination chemotherapy of sildenafil plus carboplatin and weekly taxol with carboplatin and weekly taxol in patients with previously untreated advanced non-small cell lung cancer. The study hypothesis is that sildenafil may improve the distribution and efficacy of cytotoxic anticancer agents.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hamamatsu University
• Treatments: Albumin-Bound Paclitaxel; Carboplatin; Paclitaxel; Sildenafil Citrate

Criteria

Inclusion Criteria:

• Diagnosis of histologically confirmed stage IIIB or IV non-small cell lung cancer

• Good performance status (ECOG 0-1)

• No previous treatment

• Adequate bone marrow, liver and renal functions

• Must be able to swallow tablets

• Provided written informed consent

Exclusion Criteria:

• Severe complications or a concomitant malignancy

• Contraindicated sildenafil, carboplatin or taxol

• Inappropriate patients for entry to this study, judged by the physicians